TriangleFOR PATIENTS · SOURCE READING
Targeted therapy
Source: Laryngeal Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Context: Treatment Option Overview / New types of treatment are being tested in clinical trials.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells.
Source links and citations
Monoclonal antibodies: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Cetuximab is being studied in the treatment of laryngeal cancer.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice